PAX6 mean expression across clinicopathological relevant subgroups
| n | PAX6 mean | P value | |
| WHO Grade | |||
| I | 39 | 24.3 | |
| II | 91 | 25.6 | |
| III | 42 | 34.7 | 0.089 |
| Histology | |||
| Myxopapillary | 29 | 30.9 | |
| Subependymoma | 10 | 5.0 | |
| Classic | 91 | 25.6 | |
| Anaplastic | 42 | 34.7 | 0.0020 |
| Age | 172 | 0.182 | |
| Gender | |||
| Female | 69 | 30.7 | |
| Male | 103 | 25.4 | 0.88 |
| Localisation | |||
| Infratentorial | 45 | 28.1 | |
| Spinal cord | 100 | 30.3 | |
| Supratentorial | 26 | 14.8 | 0.211 |
| Molecular Subgroup | |||
| EPN-RELA | 10 | 17.1 | |
| EPN-YAP1 | 2 | 41 | |
| SE-SUP | 5 | 6.7 | |
| PFA | 16 | 32.8 | |
| PFB | 24 | 29.3 | |
| SE-INF | 5 | 3.4 | |
| EPN-SPINE | 68 | 31 | |
| MPE | 29 | 30.9 | |
| Not classified | 13 | 15 | 0.0257 |
| Tumour type | |||
| Primary | 147 | 27.3 | |
| Recurrent | 25 | 28.4 | 0.84 |
EPN-REAL, ependymoma RELA-fusion positive; EPN-SPINE, spinal ependymoma; EPN-YAP1, ependymoma with Yap1 fusion; MPE, Myxopapillary ependymoma; PAX6, paired box 6; PFA, posterior fossa group A; PFB, posterior fossa group B; SE-INF, subependymoma infratentorial; SE-SUP, subependymoma supratentorial.